Relatively consistent
There are consistent results for a clear indication, population, formulation and outcome. It doesn't mean universal efficacy.
Ribor and boundaries
How we report clinical evidence
A conclusion about cannabinoids is valid only for the product, dose, population and result studied. We do not treat "cannabis," "THC" and "CBD" as interchangeable interventions.
Limited or mixed
There are clinical signs but studies are small, heterogeneous, contradictory or at risk of bias.
Insufficient
There's insufficient clinical evidence to sustain a useful conclusion or available data are indirect.
Evidence of absence of benefit
Proper studies do not show the expected benefits for a specific intervention and outcome.
What we review before we publish
- Type and quality of study
- Sample size and characteristics
- Product, concentration and track
- Comparison and duration
- Magnity of benefit
- Adverse and Abandoning Effects
- Conflicts of interest
- Applicability to the Colombian context
The information will be reviewed as information appears or the regulatory framework changes. Consultation Clinical Summary and our editorial policy.